When your dog has cancer, you deserve more than a PDF and a 15-minute appointment.
SciRouter Oncology is a shared workspace for you, your vet, and your specialty oncologist. Biopsy, bloodwork, imaging, genomics, treatment, quality of life — all in one record so the people caring for your dog are looking at the same picture. Powered by SciRouter's open-source biomedical model stack: the same infrastructure already running ESMFold, AlphaFold 3, DiffDock, and Boltz-2 for drug-discovery teams.
Built on the SciRouter platform that already powers
Eight canine cancers — covering roughly 80% of cases.
Each cancer has its own page: plain-language explainer, prognosis ranges, treatment landscape, recurrent mutations, questions to ask your vet, and quality-of-life notes. Every claim cites a peer-reviewed source.
Canine Lymphoma
A cancer of lymphocytes (a type of white blood cell).
Mast Cell Tumor
A tumor of mast cells, usually presenting as a skin nodule but can occur in any tissue.
Osteosarcoma
Aggressive bone cancer, typically appendicular (limb), with very high rate of micro-metastatic spread to lungs by the time of diagnosis.
Hemangiosarcoma
An aggressive cancer of blood vessel endothelium.
Canine Melanoma
A cancer of melanocytes.
Soft Tissue Sarcoma
A connective-tissue tumor that typically grows as a firm, often pseudo-encapsulated mass.
Transitional Cell Carcinoma
A malignant tumor of the urothelial lining, most commonly arising at the trigone of the bladder.
Mammary Carcinoma
Tumors of the mammary gland, ranging from benign adenomas to highly aggressive inflammatory carcinomas.
Two doors, one record. The whole picture, in one place.
Built for the days that need the most care.
Drag-drop biopsy PDFs and bloodwork — we structure it. A daily 30-second symptom log charts quality of life over time, so you and your vet can see the small changes early. A diagnosis explainer in plain language. Trials within driving distance, ranked for your dog's specific profile. Vet sharing in one click.
- Document inbox — biopsy PDFs parsed via SciRouter Gemma 4 26B
- Symptom tracker with 30-day quality-of-life chart
- Multi-pet households (Mochi has cancer; Yuki, her sister, doesn't — both fit)
- Pet-insurance integration: Trupanion, Nationwide, ASPCA, Embrace, MetLife Pet
- OHIF DICOM viewer for radiographs and CT
- English, Spanish, Portuguese, Mandarin
Tumor board in your browser.
Multi-patient roster. Per-patient genomic profile with drug-mutation matrix, off-label dosing guidance, and contraindications keyed to your patient's labs. Cohort comparator: how does this hemangiosarcoma compare to the 500+ others in our network with the same mutation profile?
- OncoKB-aligned variant annotation for every reported mutation
- Drug-mutation matrix — predicted response score per drug
- Cohort comparator — real-world outcomes from the network
- Co-management messaging with the referring DVM
- AI scribe / SOAP-note generation, oncology-specialized
- Chemo dosing calculator with breed-specific MDR1 (ABCB1) flags
Open-source models, all the way down.
SciRouter routes every step of the analysis through the same open-source biomedical model stack already in production for drug-discovery customers. No proprietary black box — every variant call, every neoantigen rank, every drug recommendation is reproducible.
- Variant calling: GATK + Mutect2 + Strelka
- RNA-seq quantification: Salmon + STAR aligned to canFam4
- Neoantigen prediction: pVACtools + NetMHCpan-4.1, calibrated for DLA
- Structure: AlphaFold 3 + ESMFold + Boltz-1
- Drug-target binding: DiffDock + Boltz-2 + Chai-1
- Imaging interpretation: MedSAM + canine-trained foundation models
We're not another genomics vendor. We're your workspace.
Sequence with FidoCure, Vidium, or any university lab — we ingest from anywhere. Use ImpriMed's chemosensitivity assay alongside our drug-mutation matrix. Run any new biomedical model against your patient on day-zero of its release.
One unified record — owner, GP, and oncologist all see the same patient, with role-appropriate detail. Co-management messaging, audit logs, and HIPAA-equivalent technical controls from day one (even though dogs aren't covered — we know vet partners need it for credibility).
PIK3CA c.3140A>G (p.H1047R), VAF 0.41 · OncoKB Level 1 (human breast cancer)
Cohort comparator: 47 PIK3CA-mutant HSA dogs in network. Median PFS on alpelisib 184 days vs 112 days on doxorubicin alone (95% CI disclosed in deep dive).
Decision support, not diagnosis
The portal informs the licensed vet's decision. Prescribing liability stays with the prescribing vet, exactly as it does today.
HIPAA-equivalent controls
Encryption at rest, role-based access, MFA, audit logs, immutable backups — even though dogs aren't legally covered. The price of credibility with vet partners.
USDA-CVB pathway, not gray zone
Personalized mRNA runs under conditional licensure or university IACUC trial wrappers — partnerships with UF, NC State, CSU, Penn.
We treat every stage with care
Through active treatment, palliative care, and — if it ever becomes part of the journey — saying goodbye. All reminders pause when you tell us to. Memorial pages, support resources, and research contribution are always optional and always on your terms.
Care for your dog today. With your consent, faster cures for every dog tomorrow.
Everything here exists to help your dog. If — and only if — you choose to share, your dog's de-identified record helps vets and researchers work toward better treatments for every dog facing this diagnosis, and eventually for the people who get the same cancers. That's how comparative oncology should have worked all along.